about
Early-life exposures to infectious agents and later cancer developmentUnderstanding the interplay between host immunity and Epstein-Barr virus in NPC patientsPosttransplant lymphoproliferative disease after pediatric solid organ transplantationClinicopathological and EBV analysis of respiratory epithelial adenomatoid hamartomaVirus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disordersThe EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and eliminationEpstein-Barr virus and skin manifestations in childhood.Repositioning antimicrobial agent pentamidine as a disruptor of the lateral interactions of transmembrane domain 5 of EBV latent membrane protein 1.T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study.Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantationGene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphomaCD8(+) T cells from mice transnuclear for a TCR that recognizes a single H-2K(b)-restricted MHV68 epitope derived from gB-ORF8 help control infection.A Gene Expression Signature That Correlates with CD8+ T Cell Expansion in Acute EBV InfectionHigh Levels of EBV-Encoded RNA 1 (EBER1) Trigger Interferon and Inflammation-Related Genes in Keratinocytes Expressing HPV16 E6/E7Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.A literature review on the patients with autoimmune diseases following vaccination against infections.Epstein-Barr virus: an important vaccine target for cancer prevention.Professional antigen presenting cells in human herpesvirus 8 infection.Higher Frequency of CD4+CXCR5+ICOS+PD1+ T Follicular Helper Cells in Patients With Infectious Mononucleosis.The immune microenvironment of human tumors: general significance and clinical impactEnhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection.Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children.Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.Epidemiology: clues to the pathogenesis of Burkitt lymphoma.Burkitt lymphoma: the role of Epstein-Barr virus revisited.T-cell therapy in the treatment of post-transplant lymphoproliferative diseaseMultiple infections and cancer: implications in epidemiology.T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized miceImmunotherapy against cancer-related viruses.EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.EBV oncogene N-LMP1 induces CD4 T cell-mediated angiogenic blockade in the murine tumor model.Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.Microbe-Induced Inflammatory Signals Triggering Acquired Bone Marrow Failure Syndromes.An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.Breastfeeding, previous Epstein-Barr virus infection, Enterovirus 71 infection, and rural residence are associated with the severity of hand, foot, and mouth disease.
P2860
Q26786103-30509C5B-229C-4D04-854C-65328AA26BB7Q26823898-B72CA39A-3EEF-4844-93FF-97CC0C616AA3Q26866013-F4DCFA62-3F0B-4AA7-8D35-150C3B14C77AQ33574479-AF3AAE1F-128B-450F-95BD-64E8329211B8Q33650689-FEB4B58B-099D-40CC-AECE-8715D4661CF8Q34277034-318C7071-137F-4076-A19D-0DA49A71056DQ34373828-1EB53B7D-1BFF-4B1F-B748-6D32B9897BA1Q34456483-2BA9070D-C442-44C1-BD49-7B3D71C77908Q34992684-874B4000-0AE1-40C3-AE6B-A5BAA27AB44CQ35060767-E35B2CFF-D77B-41F6-837B-1A900C56AA3AQ35485612-9F69E2A1-7B6B-4963-B393-3C609151EB61Q36051184-D744E149-F3C1-4186-BB19-CFF80D5EE1FFQ36120915-2C27CDF5-0CE3-4306-ADDD-39D7BD9E9FDFQ36176987-B39A27C3-937F-4B2A-B039-6EB20F03C75DQ36240353-54E0A422-09B5-48DF-8A83-C3A80DA866E9Q36241068-06E6FA5A-0BCE-4798-9D9F-7DA12E9ED010Q36255747-CFD0B6F3-4DD8-4F5B-8491-EB7B8D94699CQ36408680-5CD5E11B-A71A-4A24-A44E-16FA938D302AQ36546999-1483B4C2-2B8B-406B-BFAE-450B18BAAD4EQ37016858-7ECF2513-29C1-4F2E-B592-B8801A444CFCQ37028764-9252CE0A-32F0-4435-886A-78F1187F6506Q37139813-4FE508C4-682C-4B0B-A015-8FD8A9CB3A42Q37549726-BD0D1A4E-5C36-44EE-B949-AD418A14235EQ37676274-C0D5346A-58EA-45F0-B56B-368FC6E2D0D6Q37745980-D129EF3B-112E-4ED4-9EB6-EF2DD815D7DEQ37977130-4F795FA5-0E04-4F69-8139-0C6DD2EA8A96Q38000577-834BBE88-2F7E-4965-A98A-DC6CAA62DF4AQ38026758-B9F113ED-5A53-4810-A26C-C5D957A3C331Q38126931-1E0CB4CD-F81F-4CB7-B1D4-31B6D4C166F3Q38326876-3CCCC943-BEBC-4A61-9797-79CB2206FBAFQ38778924-A12DF83C-85DF-43E2-AEF3-107A9A884207Q38812004-F2E5E31A-F06A-4EA2-ABA3-56C9F599B616Q38822525-D1A9B543-EA60-49C9-BC35-5B24808A6394Q38890228-56B68179-728A-44AD-AF4B-B84EF031967FQ39044990-897F728E-FB40-46FE-9F82-9FE77DE967C9Q39175446-4BD63944-F717-484D-8C8D-FB10941DCFA6Q39227077-E1132AA6-C22C-41EC-940D-EF7770AE357AQ40471906-B01C89B5-8627-4E44-8885-B1F04DDC5831Q42209387-1A842CE4-BE99-4AF8-AF80-C2D936DDAB52Q42277791-985BC44C-BC35-4269-AEE9-951D5ECB8DDA
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune defence against EBV and EBV-associated disease.
@en
Immune defence against EBV and EBV-associated disease.
@nl
type
label
Immune defence against EBV and EBV-associated disease.
@en
Immune defence against EBV and EBV-associated disease.
@nl
prefLabel
Immune defence against EBV and EBV-associated disease.
@en
Immune defence against EBV and EBV-associated disease.
@nl
P2093
P1476
Immune defence against EBV and EBV-associated disease.
@en
P2093
Alan B Rickinson
Graham S Taylor
Heather M Long
P304
P356
10.1016/J.COI.2010.12.014
P577
2011-01-25T00:00:00Z